JP2023518262A5 - - Google Patents

Info

Publication number
JP2023518262A5
JP2023518262A5 JP2022556196A JP2022556196A JP2023518262A5 JP 2023518262 A5 JP2023518262 A5 JP 2023518262A5 JP 2022556196 A JP2022556196 A JP 2022556196A JP 2022556196 A JP2022556196 A JP 2022556196A JP 2023518262 A5 JP2023518262 A5 JP 2023518262A5
Authority
JP
Japan
Prior art keywords
alkyl
group
optionally substituted
cycloalkyl
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022556196A
Other languages
English (en)
Japanese (ja)
Other versions
JP7874548B2 (ja
JP2023518262A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/023222 external-priority patent/WO2021188938A1/en
Publication of JP2023518262A publication Critical patent/JP2023518262A/ja
Publication of JP2023518262A5 publication Critical patent/JP2023518262A5/ja
Application granted granted Critical
Publication of JP7874548B2 publication Critical patent/JP7874548B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022556196A 2020-03-20 2021-03-19 Phd阻害剤化合物、組成物、及び使用 Active JP7874548B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062992606P 2020-03-20 2020-03-20
US62/992,606 2020-03-20
PCT/US2021/023222 WO2021188938A1 (en) 2020-03-20 2021-03-19 Phd inhibitor compounds, compositions, and use

Publications (3)

Publication Number Publication Date
JP2023518262A JP2023518262A (ja) 2023-04-28
JP2023518262A5 true JP2023518262A5 (cg-RX-API-DMAC10.html) 2024-05-24
JP7874548B2 JP7874548B2 (ja) 2026-06-16

Family

ID=75639963

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022556196A Active JP7874548B2 (ja) 2020-03-20 2021-03-19 Phd阻害剤化合物、組成物、及び使用

Country Status (15)

Country Link
US (1) US20230159489A1 (cg-RX-API-DMAC10.html)
EP (1) EP4121426A1 (cg-RX-API-DMAC10.html)
JP (1) JP7874548B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220156890A (cg-RX-API-DMAC10.html)
CN (3) CN121085893A (cg-RX-API-DMAC10.html)
AR (1) AR121621A1 (cg-RX-API-DMAC10.html)
AU (1) AU2021240044A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022018878A2 (cg-RX-API-DMAC10.html)
CA (1) CA3176142A1 (cg-RX-API-DMAC10.html)
CO (1) CO2022014587A2 (cg-RX-API-DMAC10.html)
IL (1) IL296632A (cg-RX-API-DMAC10.html)
MX (1) MX2022011392A (cg-RX-API-DMAC10.html)
PH (1) PH12022552461A1 (cg-RX-API-DMAC10.html)
TW (1) TWI912295B (cg-RX-API-DMAC10.html)
WO (1) WO2021188938A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11713298B2 (en) 2018-05-09 2023-08-01 Akebia Therapeutics, Inc. Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
US12612367B2 (en) 2019-12-10 2026-04-28 Akebia Therapeutics, Inc. Method for producing nitrogen-containing heteroarylcarboxamide acetic acid derivative
AR121626A1 (es) 2020-03-20 2022-06-22 Akebia Therapeutics Inc Compuestos inhibidores de phd, composiciones y métodos de uso

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663327A (en) * 1984-05-23 1987-05-05 Bayer Aktiengesellschaft 1-heteroaryl-4-aryl-pyrazolin-5-ones
DE3443308A1 (de) * 1984-11-28 1986-05-28 Bayer Ag, 5090 Leverkusen 1-heteroaryl-4-aryl-pyrazolin-5-one zur verwendung als arzneimittel
DE102005019712A1 (de) * 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone und ihre Verwendung
DE102006050516A1 (de) * 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dihydropyrazolone und ihre Verwendung
DE102006050513A1 (de) * 2006-10-26 2008-04-30 Bayer Healthcare Ag Substitiuierte Dihydropyrazolone und ihre Verwendung
DE102006050515A1 (de) 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dipyridiyl-dihydropyrazolone und ihre Verwendung
WO2008121861A2 (en) * 2007-03-28 2008-10-09 Xenon Pharmaceuticals Inc. Pyrazole and pyrrole compounds useful in treating iron disorders
WO2010005851A1 (en) * 2008-07-08 2010-01-14 Xenon Pharmaceuticals Inc. Combination therapy for treating iron disorders
SG172803A1 (en) 2008-12-29 2011-08-29 Sanofi Sa Derivatives of 2-pyridin-2-yl-pyrazol-3(2h)-one, preparation and therapeutic use thereof as hif activators
US8987461B2 (en) 2012-12-06 2015-03-24 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
AP2015008783A0 (en) * 2013-03-29 2015-10-31 Takeda Pharmaceutical 6-(5-hydroxy-1h-pyrazol-1-yl) nicotinamida derivatives and their use as phd inhibitors
CN106831735B (zh) * 2017-01-23 2019-10-11 牡丹江医学院 一种治疗骨质疏松的杂环化合物及其制备方法和用途

Similar Documents

Publication Publication Date Title
JP2023518543A5 (cg-RX-API-DMAC10.html)
JP2023171659A5 (cg-RX-API-DMAC10.html)
JP2024509818A5 (cg-RX-API-DMAC10.html)
JP2021088610A5 (cg-RX-API-DMAC10.html)
JP2023518953A5 (cg-RX-API-DMAC10.html)
JP2005514420A5 (cg-RX-API-DMAC10.html)
JP2021514001A5 (cg-RX-API-DMAC10.html)
JP2022521825A5 (cg-RX-API-DMAC10.html)
JP2021513967A5 (cg-RX-API-DMAC10.html)
JP2009529540A5 (cg-RX-API-DMAC10.html)
JP2020523351A5 (cg-RX-API-DMAC10.html)
JP2023531709A5 (cg-RX-API-DMAC10.html)
JP2017504641A5 (cg-RX-API-DMAC10.html)
JP2005505595A5 (cg-RX-API-DMAC10.html)
JP2018538304A5 (cg-RX-API-DMAC10.html)
JP2009534398A5 (cg-RX-API-DMAC10.html)
JP2018501285A5 (cg-RX-API-DMAC10.html)
JP2008510828A5 (cg-RX-API-DMAC10.html)
RU2000132199A (ru) Гетероциклические соединения и способы лечения сердечной недостаточности и других нарушений
TW200519092A (en) Malonamide derivatives
JP2019500315A5 (cg-RX-API-DMAC10.html)
JP2005511545A5 (cg-RX-API-DMAC10.html)
JP2020504707A5 (cg-RX-API-DMAC10.html)
JP2019527235A5 (cg-RX-API-DMAC10.html)
JP2023531495A5 (cg-RX-API-DMAC10.html)